Lupin Secures USFDA Approval For Generic Hypertension Drug

India Pharma Outlook Team | Monday, 15 January 2024

 India Pharma Outlook Team

Lupin, a leading pharmaceutical company, stated that it has gotten approval from the US Food and medicine Administration to offer a generic medicine to treat migraines and hypertension. The Mumbai-based business has gained approval from the US Food and Drug Administration (USFDA) for Propranolol Hydrochloride extended-release capsules in several strengths, according to Lupin Ltd in a regulatory filing to the stock exchanges.

The company's product is the generic version of ANI Pharmaceuticals' Inderal LA extended-release capsules, it added. The product will be manufactured at the company's Pithampur-based manufacturing plant, the drug firm stated, as per livemint.   This is the third fresh launch announced by the corporation in the last week. The other two approvals were Varenicline tablets, which are used to treat smoking addictions and dry eye disease, and bromfenac ophthalmic solution, which is used to treat inflammation and pain in patients who have had cataract surgery.

Propranolol Hydrochloride Extended-release Capsules USPs are used to control hypertension. They can be used alone or in combination with other antihypertensive medications, especially thiazide diuretics. According to IQVIA MAT statistics for November 2023, Propranolol Hydrochloride extended-release capsules had an estimated annual sales value of $71 million in the United States.

Lupin ranks among the world's largest generic pharmaceutical firms in terms of revenue. Paediatrics, cardiovascular, anti-infectives, diabetology, asthma, and tuberculosis are among the company's primary emphasis areas. Lupin was developed in 1968 by Desh Bandhu Gupta, a chemical professor at BITS Pilani in Rajasthan. 

© 2024 India Pharma Outlook. All Rights Reserved.